| 영문 | protein | 한글 | 단백질 |
|---|---|---|---|
| 설명 | 탄소, 수소, 산소, 질소, 황을 함유하고 있는 유기화합물로, 모든 세포의 원형질을 이루고 있는 기본 구성물질이다. 단백질은 그 단위인 아미노산들이 펩티드결합에 의해 결합되어 있으며, 보통 20개의 아미노산들이 다른 순서와 조성을 가지고 배열되어, 독특한 하나의 단백질을 형성하게 된다. |
||
| 영문 | testicular feminization syndrome | 한글 | 고환여성화증후군 |
|---|---|---|---|
| 설명 | 이차성장을 포함하여, 외성기의 발육은 여성이지만 고환이 존재하고, 자궁과 자궁관이 결핍되어 있는 남성 거짓남녀한몸증의 극단적 형태이다. 이것은 테스토스테론의 작용에 대한 말단기관의 저항에 기인한다. |
||
| 영문 | irritable bowel syndrome | 한글 | 과민성대장증후군 |
|---|---|---|---|
| 설명 | 배변장애, 복통, 복부팽만 등의 증상이 있으나 기질적인 병변이 없음이 확인된 예를 총망라한 임상 증후군이다. 가장 흔한 소화기 질환이며(전소화기 환자의 70~80%) 가장 흔한 질병(전체 인구의 약 20%)이다. 여성이 남성에 비해 2배 정도 많이 발생하며 30대 및 40대에서 호발하고 선진 공업국에서 많이 발생한다. 진단을 위해서는 병력 청취가 가장 중요하고 각종 검사로서 기질병을 제외해야 한다. 치료로는 안정요법(정신과적 면담 및 심리요법, 신경안정제), 식사요법(고섬유질 음식 섭취, 자극성 음식 피하기), 약물 요법(창자경련 진정제, 변비 완화제, 지사제) 등을 사용한다. |
||
| 영문 | withdrawal syndrome | 한글 | 금단증후근 |
|---|---|---|---|
| 설명 | 알코올, 마약, 바비투르산계 최면약 등의 약물을 장기간 복용하여 약물이 없이는 견딜 수 없게된 뒤, 그 약물을 중지한 경우에 나타나는, 고통이 수반되는 신체적 증상을 말한다. 연속 복용의 기간에 따라 증상이 무거워진다. 통상적으로 구토, 설사, 혈압상승, 빠른맥, 땀남, 혼수 등의 증상이 나타난다. |
||
| 영문 | organic brain syndrome | 한글 | 기질적 뇌증후군 |
|---|---|---|---|
| 설명 | 뇌의 기질적인(organic-:이 말은 기능적인(functional)에 반하는 말로써) 모든 검사를 시행하면 어떤 이상을 발견할 수 있다는 뜻이다. 바꾸어 말하면, 기능적인 이상에 의한 뇌증후군은 어떠한 검사로도 이상을 발견할 수 없으나 분명히 환자에게 이상증상이 나타났을 때 이를 묶어서 말한다. 이상에 의해 신경학적인 이상을 나타내는 일련의 병적현상을 모두 통틀어 말한다. 이 병은 흔히 보아 마치 정신병환자처럼 말을 횡설수설하고, 알아들을 수 없는 말을 하며, 때로는 다른 사람에게 공격적인 성향을 나타내기도 한다. 그리고 다른 사람과 도저히 교류를 할 수 없는 정서를 나타내기도 한다. 그러나, 이 병이 다른 정신병과 구별되는 특징적인 증상은 먼저, 의식의 혼탁이 동반되는 경우가 많고, 또한 그 증상의 정도가 변한다는 것이다. 즉, 아침에는 정상적인 행동을 하다가 오후가 되면, 의식이 흐려지면서 말을 횡설수설한다면, 이는 기질성뇌증후군일 가능성이 높다. |
||
| LNP | large neuronal polypeptide |
|---|---|
| NCL | neuronal ceroid-lipofuscinosis; nucleolin |
| SCN1A | sodium channel, neuronal alpha-subunit type 1 |
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
| PPS | Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc... |
| NAIP | Neuronal Apoptosis Inhibitor Protein |
|---|---|
| DND | Delayed neuronal death |
| INCL | Infantile neuronal ceroid lipofuscinosis |
| IND | Intestinal Neuronal Dysplasia |
| JNCL | Juvenile neuronal ceroid lipofuscinosis |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
|---|---|
| cell adhesion molecules, neuronal | Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue. (12 Dec 1998) |
| primary neuronal degeneration | <disease> A progressive, neurodegenerative disease characterised by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language. The cause of nerve cell death is unknown but the cells are recognised by the appearance of unusual helical protein filaments in the nerve cells (neurofibrillary tangles) and by degeneration in cortical regions of brain, especially frontal and temporal lobes. Alzheimer's disease is the most common cause of dementia. (22 May 1997) |
| neuronal | <anatomy> Pertaining to a neuron or neurons (= conducting cells of the nervous system). (18 Nov 1997) |
| neuronal ceroid-lipofuscinosis | A heritable lipidosis with cytoplasmic inclusions staining for ceroid and lipofuscin. Clinically the patient has progressive dementia, retinal degeneration, seizures, and myoclonic jerks. It was formerly thought to be related to tay-sachs disease but the biochemical defect is as yet undetermined. Named according to age of onset: jansky-bielschowsky disease, 2-4 years; batten-spielmeyer-vogt disease, 5-11 years; and kufs disease, adult. (12 Dec 1998) |
| neuronal differentiation | Acquisition during development of specific biochemical, physiological and morphological properties by nerve cells. (18 Nov 1997) |
| neuronal guidance | <cell biology> General term for mechanisms that ensure correct projections by nerve cells in developing and regenerating nervous systems. Implies accurate navigation by growth cones, the highly motile tips of growing neuronal processes. See: growth cone collapse. (12 Mar 1998) |
| neuronal hyperplasia | Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis. Synonym: hyperganglionosis, neuronal intestinal dysplasia. (05 Mar 2000) |
| neuronal intestinal dysplasia | Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis. Synonym: hyperganglionosis, neuronal intestinal dysplasia. (05 Mar 2000) |
| neuronal plasticity | Ability of nerve cells to change their properties for example by sprouting new processes, making new synapses or altering the strength of existing synapses. See: long-term potentiation. (18 Nov 1997) |
| neuronal polarity | Distribution of specific functions to discrete cellular domains: for example axons and dendrites that have different molecular composition, morphology and ultrastructure and perform different functions. (18 Nov 1997) |
| infantile neuronal degeneration | <neurology, paediatrics> Degenerative disorder of infants with widespread neuronal loss in thalamus, cerebellum, pons, and spinal cord, resembling infantile muscular atrophy. (05 Mar 2000) |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
Synonyms : N-WASP Wiskott-Aldrich Syndrome Protein, WASL Wiskott-Aldrich Syndrome Protein, Wiskott-Aldrich Syndrome Gene-Like Protein, N WASP Protein, N WASP Wiskott Aldrich Syndrome Protein, Neuronal Wiskott Aldrich Syndrome Protein
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|